As a step to understanding the relationship between the development of drug-resistant CMV and disease progression, we analyzed the clinical, virologic, and molecular aspects of CMV disease in an AIDS patient with disseminated CMV who died following 20 months of CMV treatment. Genotypic and phenotypic analyses indicated that the patient was infected with the same ganciclovir-resistant strain in his blood, urine, and cerebrospinal fluid (CSF). The presence of ganciclovir-resistant CMV was associated with an increase in the level of CMV DNA in plasma, and both the development of ganciclovirresistant virus and an elevation in plasma DNA levels preceded the development of CMV -related CNS disease.
Material and Methods

Clinical summary (figure lA -C).
A 48-year-old white homosexual man with AIDS (37 CD4 lymphocytes/mm") was given ganciclovir induction therapy (5 mg/kg twice daily) for CMV colitis. Shortly thereafter, CMV retinitis was identified in the patient. The retinitis was treated with and responded to the induction doses of gancic1ovir. During a 5-month period, the patient underwent 3 episodes of ganciclovir induction treatment followed by maintenance therapy (5 mg/kg once daily) and was then switched to foscamet induction therapy (90 mg/kg twice daily) followed by maintenance treatment of 120 mglkg/day for reactivation of CMV retinitis. However, after 10 weeks, foscamet therapy was discontinued because of drug intolerance, and ganciclovir therapy was reinstituted.
After 14 months of anti-CMV treatment, the patient had 4 CD4 lymphocytes/mrrr', and retinitis progression in the right eye, and later the left eye, was not responding to ganciclovir or foscamet treatment. Intraocular injections of cidofovir (20-40 J1g) resulted in transient stabilization of retinitis; however, vision in the right eye was subsequently lost. After 17 months of anti-CMV therapy, the patient developed signs of polyradiculopathy, including pro-TID 1996;173 (June) gressive weakness of the lower extremities, urinary retention, and fecal incontinence. CMV was cultured from urine, blood, and CSF. The polyradiculopathy did not respond to induction doses of ganciclovir or foscarnet, and the patient died 3 months after the first symptoms of CNS disease appeared. Cells and virus. CMV isolates cultured from peripheral blood, urine, and CSF specimens were established and maintained in human foreskin fibroblasts. Viral cultures were maintained in Dulbecco's MEM (DMEM) supplemented with 10% fetal bovine serum, 2 roM L-glutamine, 100 U/mL penicillin, 0.01% streptomycin, and 2.5 J.tg/mL amphotericin B (DMEM-lO) and stored as cellassociated stocks in DMEM-20, 10% dimethyl sulfoxide under liquid nitrogen.
Polymerase chain reaction (PCR) analysis. The procedure for qualitative PCR analysis of plasma specimens has been described previously [6] . In quantitative competitive PCR (QC-PCR) reactions, plasma PCR conditions were modified by the addition of 1000 copies of a competitor DNA template. The competitor DNA sequence is identical to the fragment amplified in the qualitative plasma PCR except for the insertion of a 20-bp sequence. Fragments amplified from the internal competitor and from the CMV DNA present in the plasma were hybridized to a 32P-end-Iabeled probe and resolved by polyacrylamide gel electrophoresis. A standard curve was calculated using least squares analysis, and CMV genome copy number in plasma specimens was quantitated using the ratio of wild type to competitor PCR product.
Drug sensitivity. Antiviral drugs were provided by the following suppliers: ganciclovir, Roche Bioscience (Palo Alto, CA); foscamet, Astra Pharmaceutical Products (Westborough, MA); and cidofovir, Gilead Sciences (Foster City, CA). Drug ID so values were determined by plaque reduction assays, using a 0.3% agarose overlay to inhibit secondary plaque formation, as described previously [7] . Quadruplicate wells of human foreskin fibroblasts, in 24-well cluster dishes, were infected with~100 CMV-infected cells and maintained at ganciclovir concentrations of 1, 5, 10, 25, and 50 tJ,M or at foscarnet concentrations of 200, 400, 600, 800, and 1000 J.tM. Ganciclovir and foscarnet resistance are defined by ID so values :;:;.9 and :;:;.300 tJ,M, respectively (unpublished data).
Heterogeneity in CMV isolates. PCR and restriction fragment length polymorphism (RFLP) were used to distinguish clinical strains of CMV [8] . RsaI digestion products of a 2-kb fragment amplified from infected-cell DNA were resolved in 2% agarose.
Sequence analysis. UL97 gene sequences were determined using the fmol DNA sequencing system (Promega, Madison, WI) with 32P-end-Iabeled primers. A sequencing template was PCRamplified from infected-cell DNA using primers 5'kin-43 (5'-GGTAGCTAGTGCAGCCTTAGG-3') and 3'kin-2376 (5'-AGA-CAGACGCAGCACCGTAAA-3'). Sequencing primers were spaced~300 nt apart.
Results
Detection and quantification of CMV DNA during disease progression. Of 7 sequential plasma specimens obtained over the course of the patient's treatment for CMV disease, 5 were positive for CMV DNA by plasma PCR analysis. Of note, each of the 5 positive specimens was drawn in the later stages of UL97 encodes a protein with phosphotransferase activity that is required for the activation of ganciclovir, and mutations in UL97 are associated with ganciclovir resistance of clinical CMV isolates [7, [10] [11] [12] . To determine if the ganciclovir resistance of blood-, urine-, and CSF-derived CMV isolates each arose from the same genetic alteration, the UL97 gene sequence was determined. A single amino acid substitution of valine for methionine at aa 460, resulting from an alteration at nt 1378 (adenine to guanine), was detected in the carboxy-terminal region of the phosphotransferase, a substitution shown previously to confer ganciclovir resistance [ disease. During this time, CMV was repeatedly cultured from peripheral blood, and CMV DNA in the plasma increased from 19 to 1500 copies/rd. ( figure ID) . Together, these data suggest that a high rate of CMV replication occurred during this period. QC-PCR analysis indicated that the patient's CSF contained 48,240 copies/ J.LL of CMV DNA during progression of CMVrelated polyradiculopathy compared with 1500 copies/J.lL in plasma.
Ganciclovir-resistant CMV is associated with disseminated disease. While the patient was receiving ganciclovir, there was an increase in the plasma level of CMV DNA. This suggests that CMV in this patient was replicating under conditions of minimal restriction and that resistance to ganciclovir had developed. To determine if reduced ganciclovir sensitivity could be a contributing factor in disease progression, we determined ganciclovir ID so values for each virus isolate (figure 2). The ganciclovir ID so value for each isolate was in the resistant range and varied from 15.7 to 48.4 J.lM In contrast, foscamet ID so values ranged from 134 to 246 J.lM, indicating that resistance to foscamet had not developed.
Genotypic assessment ofheterogeneity in ganciclovir-resistant isolates. It has been shown that multiple strains of CMV can simultaneously infect persons with AIDS [9] . To assess the heterogeneity of CMV strains cultured from the blood, urine, and CSF of this patient, a rapid PCR-and RFLP-based analysis was done. Watanabe et al. [8] demonstrated that RsaI digestion of a polymorphic CMV region can effectively differentiate strains of CMV. Using this procedure, we found the same strain of CMV to predominate in each of the 7 isolates (figure 2).
Discussion
Lumbosacral polyradiculopathy associated with CMV infection of the CNS occurs in '"" 1% of persons with AIDS [1] . The clinical presentation and diagnosis of this syndrome have been described, and strategies for treatment have been proposed [1] . Anti-CMV therapy has been found to stabilize or improve the symptoms of polyradiculopathy in 30%-50% of patients [2, 3] . Treatment failure has been associated with the development of antiviral drug resistance (reviewed in [13] ). The presence of ganciclovir-resistant CMV in the CSF of patients with polyradiculopathy has been reported and typically occurs in persons who have received several months of ganciclovir treatment for CMV retinitis [4, 5, 14] .
Issues critical to the development of effective treatments for CMV infections that progress to the CNS include the identification of early markers of disease progression and an understanding of the relationship between the dissemination of infection and the development of drug resistance. In this report, we described a patient with AIDS who developed progressive CMV disease, including involvement of the CNS, despite extensive antiviral treatment.
CMV isolates cultured from 'multiple sites, including the CSF, were ganciclovir resistant and ofthe same strain, as determined by RFLP analysis. Further, CMV cultured from multiple sites were found by direct sequencing to contain the same methionine-to-valine mutation at aa 460 within the phosphotransferase gene (a mutation previously shown to confer ganciclovir resistance). Quantitative PCR of plasma CMV DNA demonstrated an increase in virus load with subsequent spread to the CNS, with the level of CMV DNA in the CNS being 30-fold the level in plasma. Although the patient had recurrent CMV retinitis, CMV DNA was not detected by culture or PCR analysis of plasma during the initial reactivations. The subsequent detection of CMV DNA in plasma coincided with the appearance of ganciclovir-resistant virus.
Multiple strains of CMV and strains with different drug sensitivities can simultaneously infect persons with AIDS [9, 15] ; however, the patient in this report had 1 predominant CMV strain cultured from his blood, urine, and CSF. Ganciclovirresistant virus was isolated from this patient prior to clinical manifestations of CMV dissemination to the CNS. Therefore, the development of drug resistance in CMV appears to have preceded virus dissemination. Detection of the same genetic alteration, known to confer ganciclovir resistance in CMV cultured from the blood, urine, and CSF, supports this supposition. Moreover, the nature of disease progression and the lack of heterogeneity in CMV isolated from different sites argues against the notion that CMV-related neuropathies may have developed from reactivation of CMV within cells of the CNS.
Others have suggested that the selection of ganciclovir-resistant CMV could occur in the CSF because ganciclovir concentrations reach only 40%-50% of corresponding plasma levels [5] . Our findings indicate that CMV levels within CSF can be many times greater than levels in plasma. Although drug resistance in this patient developed prior to infection of the CNS, high virus load within the CNS may be an additional risk factor for selection of CMV strains that are resistant to antiviral therapy.
In this report, we provide evidence that multi focal CMV disease can be attributed to the dissemination of 1 drug-resistant CMV variant. Our findings suggest that CMV resistance to antiviral drugs should be considered when patients develop CNS disease while on treatment for CMV retinitis. In addition, quantification of CMV DNA in plasma and genotypic analysis of CMV DNA in persons with AIDS may provide useful markers of CMV disease progression and emergence of antiviral resistance.
